| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Sorafenib | GDSC1000 | pan-cancer | AAC | 0.0074 | 0.9 |
| mRNA | OSU-03012 | GDSC1000 | pan-cancer | AAC | -0.0044 | 0.9 |
| mRNA | pluripotin | CTRPv2 | pan-cancer | AAC | 0.0044 | 0.9 |
| mRNA | Cyclopamine | GDSC1000 | pan-cancer | AAC | 0.0066 | 0.9 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.02 | 0.9 |
| mRNA | Cytarabine | GDSC1000 | pan-cancer | AAC | -0.004 | 0.9 |
| mRNA | rTRAIL | GDSC1000 | pan-cancer | AAC | -0.0039 | 0.9 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.0049 | 0.9 |
| mRNA | triptolide | CTRPv2 | pan-cancer | AAC | -0.0031 | 0.9 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.0032 | 0.9 |